Status
Conditions
Treatments
About
To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). To evaluate the efficacy of HSCT from mismatched family or unrelated donors (MMD) as compared to HSCT from MSD/MD. To determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. To prospectively evaluate and compare the incidence of acute and chronic GvHD after HSCT from MSD, from MD and from MMD.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
all patients with ALL (except for patients with B-ALL) who fulfil the following criteria:
age at time of initial diagnosis or relapse diagnosis, respectively
≤18 years
indication for allogeneic HSCT
complete remission (CR) is achieved before SCT
written consent of the parents (legal guardian) and, if indicated, the minor patient via "Informed Consent Form"
no pregnancy
no secondary malignancy
no previous HSCT
HSCT is performed in a study participating centre.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
552 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal